To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

type-2-diabetes

Type 2 Diabetes

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
<a href="${link:{uuid:{edff588a-de09-4893-a850-fff622441572},repository:{dam},path:{/Portal/UK/Prescribing-links/Admelog.pdf}}}" target="_blank">Prescribing Information (GB only)</a>

<h2>Head-to-head studies Admelog® vs Humalog®</h2>

<h3>Similar PK/PD profile1</h3>
PK/PD profiles in the biosimilar, Admelog, were similar to the EU-approved Humalog in adult males with Type 1 diabetes1

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

<h3>Similar mean HbA1C reduction2,3</h3>
Similar mean HbA1C reduction from baseline to Week 26 in Admelog and Humalog groups, in both Type 1 and Type 2 diabetes2,3

<h3>Similar long-term safety and tolerability profiles2,3</h3>
Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Admelog and Humalog groups in Type 1 and Type 2 diabetes2,3

Abbreviations

<a href="/uk/type-2-diabetes">SEE MORE FROM SCIENCE</a>

<h2>Get in touch with the Diabetes Team</h2>

Admelog® (insulin lispro 100 units/mL)
   

Admelog® (insulin lispro 100 units/mL) Prescribing Information (GB only)

Head to Head Studies

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

<a href="${link:{uuid:{62efcdcd-db16-49b4-8041-55c212a401fa},repository:{dam},path:{/Portal/UK/Prescribing-links/Trurapi-PI-GB-April-2023.pdf}}}" target="_blank">Prescribing Information (GB only)</a>

<h2>Head-to-head studies Trurapi®&nbsp;vs NovoRapid®</h2>

<h3>Similar PK/PD profile in adults with T1DM1</h3>
PK/PD profiles in the biosimilar Trurapi®, were similar to the UK and EU-approved NovoRapid®&nbsp;and US-approved Novolog®&nbsp;in patients with T1DM.1&nbsp;

<h3>Similar mean HbA1C&nbsp;reduction in adults with T1DM and T2DM2</h3>
At week 26, HbA1C&nbsp;was -0.38% for Trurapi®&nbsp;group vs -0.30% for NovoRapid®/NovoLog®&nbsp;group. Similar mean HbA1C reduction from baseline to Week 26 in Trurapi®&nbsp;and NovoRapid®/Novolog®&nbsp;groups were observed in patients with either T1DM or T2DM.2

<h3>Similar long-term safety and tolerability profiles in adults with T1DM and T2DM2,3</h3>
Similar incidence rates of any hypoglycaemic events (≥1 event) in both the T1DM and overall population were observed in both Trurapi®&nbsp;and NovoRapid®/Novolog®&nbsp;groups.2,3
For more information and for data from the 6-month safety extension trial, download the clinical summary.&nbsp;

<h2>Want to know more about the bioequivalence data?</h2>

<a href="/uk/type-1-diabetes">SEE MORE FROM SCIENCE</a>

Trurapi®▼ (insulin aspart 100 units/mL)  

Trurapi®▼ (insulin aspart 100 units/mL) Prescribing Information (GB only)

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>Addition of Toujeo® to GLP-1 RA was associated with significantly improved glycaemic control.9</h3>
DELIVER-G real-world retrospective analysis.
A real-world retrospective analysis in insulin-naïve adults with T2D inadequately controlled on GLP‑1 RA with or without oral antidiabetic drugs (N=271).9
DELIVER-G was a retrospective analysis of 271 people with Type 2 diabetes receiving GLP‑1 RA therapy who were insulin‑naive prior to subsequent treatment intensification with Toujeo® (insulin glargine 300 U/mL). DELIVER‑G analysed data from a large US electronic medical record data source (IBM® Explorys).9

Safety Profile

References

Lantus® (insulin glargine 100 units/mL) Prescribing Information GB

Lantus® (insulin glargine 100 units/mL) Prescribing Information NI

Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

<h2>Programme for Injectable Therapies for People with Type 2 Diabetes</h2>

<h3>January 2024 - 2025</h3>
To register your interest in PITstop contact your local representative, or use the form below to get in touch and find a representative in your area.
Registering does not guarantee a place on PITstop

An accredited virtual promotional training course held over 2.5 days that supports healthcare professionals who are managing people with Type 2 diabetes on more complex regimens, including GLP-1 and insulin initiation.

<h4>Programme summary</h4>
Expect a variety of different topics on devices, insulins and other injectable therapies including:
<ul>
 <li>Revision of diabetes oral medications</li>
 <li>GLP-1 agonists including initiation using a structured care pathway</li>
 <li>Detective work at review appointments focusing on injectables</li>
 <li>Insulin safety (self-directed learning)</li>
 <li>Working through the PITstop insulin pathway to assess for insulin, initiate an appropriate insulin regimen and support the patient for the first 6 months: a case study approach</li>
 <li>Dietary considerations and insulin, including minimising weight gain</li>
 <li>Embedding the learning and university accreditation</li>
</ul>

<h4>Who is this course suitable for?</h4>
GPs, Nurse Practitioners, Practice Nurses, Clinical Pharmacists and Physician Associates (who are working as part of a practice diabetes team), already experienced in providing a diabetes service. Only HCPs who are patient facing and have the ability to initiate and prescribe injectables post the course should apply.
New to post DSNs identified as requiring training at this level, may also be suitable for this course.
Delegates must have completed a diabetes course to foundation level or be able to provide evidence of self-directed learning, focusing on the oral diabetes medication pathway. &nbsp;Suitable courses include Pre-PITstop, Warwick Certificate in Diabetes or Bradford Diabetes Certificate. You will be required to evidence this within your application.
Delegates will be required to have a named mentor in place to support completion of the competency framework post the course. &nbsp;Details of the mentor will be required at the application process. &nbsp;New to PITstop mentors will be invited to complete a ½ day mentor workshop by PITstop.

<h4>Interested?</h4>
If you are interested in attending a course please contact your local representative, or use the form below to get in touch and find a representative in your area.

Delegates who do not meet the course suitability criteria will not be registered onto the programme or may be contacted for further information. &nbsp;You will receive notification from Sanofi within 1 month once you have submitted your application confirming if you have been allocated a place on the course.

<h3>2024/25 Course Dates</h3>
Find below the dates for the 2 and a half day courses, starting in 2024.

This educational programme is organised and funded by Sanofi. The PITstop for Diabetes course content has been independently developed and will be delivered by PITstop for Diabetes on behalf of Sanofi. Sanofi have had no input or involvement in the creation of these materials but has reviewed the content to ensure compliance with the ABPI code of practice. Adverse event reporting and prescribing information is available at the meetings.

If you would like to contact us further to discuss your place please either reach out to your local representative or email us at <a href="mailto:SanofiPITstop@sanofi.com">SanofiPITstop@sanofi.com</a>

Community Diabetes Specialist Nurse

Heidi Irons

Get in touch with the Diabetes Team

This course is intended for healthcare professionals in Great Britain (England, Scotland, Wales) only.

Pitstop | Diabetes

Prescribing information is available by clicking the links at the bottom of the page

<h2>Recording</h2>
Length: 15:49

Paradigm 2024:
Lesley Mills

<h2>Recording</h2>
Length: 22:21

Paradigm 2024:
Anne Goodchild

Ketan Dhatariya&nbsp;&nbsp;

<h2>Recording</h2>
Length: 17:19

Paradigm 2024:
Ketan Dhatariya 

Ask us your questions about our products, patient materials or organising a meeting.

Type 2 Diabetes

Latest Articles

Head to Head Studies

Head to Head Studies

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

Latest Resources

Diabetes patient support

Latest Events

Pitstop | Diabetes

Latest Education

Paradigm 2024: Lesley Mills

Paradigm 2024: Anne Goodchild

Paradigm 2024: Ketan Dhatariya